8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (May 4, 2010)

Filed May 4, 2010For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on May 4, 2010, to report its first-quarter 2010 financial results. The key information, contained in a press release dated May 4, 2010, is incorporated by reference into this filing, making it an official disclosure of the company's performance for the period ending March 31, 2010. Investors should refer to the press release (Exhibit 99) for specific details regarding revenue, earnings, and any significant operational updates or forward-looking statements made by the company during this period. This 8-K serves as notification of the release of these financial results. While the 8-K itself does not contain the detailed financial data, it directs investors to the attached press release, which is the primary source for understanding Pfizer's Q1 2010 financial condition and operational outcomes. The filing indicates that the company has met its reporting obligations for this quarter.

Key Highlights

  • 1Pfizer Inc. (PFE) announced its first-quarter 2010 financial results via an 8-K filing.
  • 2The results were detailed in a press release dated May 4, 2010, which is included as Exhibit 99.
  • 3The press release is incorporated by reference into the 8-K filing, making it an official disclosure.
  • 4Investors can find specific Q1 2010 financial performance data within the referenced press release.
  • 5The filing date was May 4, 2010, with the event date of the financial results announcement being May 3, 2010.
  • 6The 8-K primarily serves to officially disseminate the quarterly financial results as per regulatory requirements.

Frequently Asked Questions

The main purpose of this 8-K filing by Pfizer Inc. is to officially report its financial results for the first quarter of 2010. The detailed financial information is provided in an accompanying press release.

The detailed financial results for Pfizer's first quarter of 2010 are located in the press release dated May 4, 2010, which is included as Exhibit 99 to this 8-K filing and incorporated by reference.

This 8-K filing itself does not contain specific financial metrics. It directs investors to the press release (Exhibit 99) for details on Pfizer's first-quarter 2010 results, which would typically include revenue, earnings per share, and other key financial performance indicators.

This 8-K filing is primarily for reporting historical financial results for the first quarter of 2010. Any forward-looking statements, including new guidance or outlook, would be found within the content of the press release (Exhibit 99) itself.